Leucogen
Active substance
ATC code
Species
Cats
Indications
Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
The onset of immunity has been demonstrated from 3 weeks after the primary vaccination.
After the primary vaccination course, the duration of immunity lasts for one year.
Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated.
Dose to be administered and administration route
Subcutaneous use.
Shake the vial gently and administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.
Primary vaccination:
- first injection in kittens from eight weeks of age
- second injection 3 or 4 weeks later.
Maternally derived antibodies can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.
Re-vaccinations:
Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years.
Adverse reactions
A moderate and transient local reaction (<2 cm) is commonly observed after the first injection. This local reaction could be a swelling, an oedema or a nodule and resolves spontaneously within from 3 to 4 weeks at the most. After the second injection, and subsequent administrations, this reaction is markedly reduced.
The transient signs following vaccination such as hyperthermia (lasting 1 to 4 days), apathy and digestive disturbances (such as emesis and diarrhoea) may also be commonly observed.
Pain at palpation, sneezing or conjunctivitis may be noted in rare cases. This resolves without any treatment.
Anaphylactic reactions have been reported in very rare cases. In case of anaphylactic shock, appropriate symptomatic treatment should be administered.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
